OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I don't think many take notice of the Independent, there were hardly any sells in first 2hrs of trading this morning, It's fear of a rights which as I have said is very unlikely.

Good news - it might halt the decline. In fact, I am almost tempted to buy back in.

Oxford Biomedica licenses Lentivector to Sigma-Aldrich
AFX

LONDON (AFX) - Oxford Biomedica PLC said it has licensed its Lentivector technology to Sigma-Aldrich Corp for the reagent and research tool market.

This strategic alliance identifies Sigma-Aldrich as Oxford BioMedica's exclusive global partner in the development and marketing of research products based on the LentiVector technology, the company said.

Under the agreement, which gives Sigma-Aldrich the exclusive right to sublicense the technology for research purposes, Oxford BioMedica will receive an upfront payment, annual minimum payments and royalties on sales.

In addition Sigma-Aldrich has first rights to negotiate for a license to develop a new range of products based on Oxford BioMedica's EIAV-based LentiVector technology.

And Sigma-Aldrich has committed to an equity investment of 5 mln usd in Oxford BioMedica, to be completed before Jan 31 2006.

Other financial terms were not disclosed.

Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types. It can be used both in therapeutic products and as a drug discovery tool.

newsdesk@afxnews.com
AFX News Limited 2005. All rights reserved.

I don't understand the deal, are oxb just selling the rights to licence the technology where oxb still receive royalties on ultimate sales of products using the technology as a result and therefore what's in it for Sigma? Could be very good for OXB but I'm not sure??

Rob - it involves some down payments which presumably delays the need to issue more equity to fund Trovax trials? Sigma will, in effect, make their money on a commission basis.

Excellent news this week, Buys outnumbering sells 3 : 1, mms lowering on a medium sell but not raising on a similar buy, they've done this twice this week down to 32p so looks like we're heading down below that to prob 27, crazy i know but they will attract the sellers this way.

I totally agree with your views Rob. The problem is that OXB has few opportunities to come out with a blockbuster announcement in the next couple of months - even Kingman was talking about a period of up to 12 months to sign up a Trovax partner. So, with a rights issue rumour always bubbling away under the surface, the sp will probably continue its recent downward movement. I sold in the low 40's but would be very happy to buy back in at anything around the 28/29p mark.

On the other hand of course there's the takeover speculation that resurfaces on a dip and Oxb is becoming more attractive by the month to any Pharm co wishing to broaden its portfolio of prods in the pipeline. 2006 will be an incredible yr for Oxb and a buy at sub 30 is going to be a steal, good luck.

someone sold 500 shares and they put the pice down!! lol

LOL, someone just bought 500 and they raised it again.. fair enough! mm must be reading this thread

and forget all the 50k, 15k etc, 500 shares again, sorry 900 ooh, and raised the price. I know i'm talking to myself here and that its not that interesting but i haven't got much to do today. :)

296 reduced price

just shows what a nonsense this sp movement this week has been. its all oil and mining at the moment but remember:

The Time could really be good now for OXB. The most attractive investment opportunities often arise in sectors which have done little to set investors' pulses racing over recent years. Investors' attitudes to them can become dismissive, so they spend little time examining them closely. Spotting when things are about to turn around is the key. OXB has the potential of several Blockbuster drugs and the years of research and trials are starting to pay off with some very exciting results (see co. website and news releases for more info)

On top of that is the cyclical nature of the Biotech sector and from the graphs of OXB and the sector, the chances of a Biotech sector rally are high. According to Framlington this area appears to be priced about 35% below its historical average, hopefully giving plenty of scope for prices to increase. In addition, as the industry has begun to mature there is a large pipeline of new products coming through.

And on top of that, there are big noises from large predators who are eagre to get their hands on the Bio Blockbusters of the future:

From Times Online 1/8/05: http://business.timesonline.co.uk/section/0,,9068,00.html

JAPANS biggest pharmaceutical group has amassed a 1.5 trillion yen (8 billion) war chest and is planning an acquisition spree as it vies for global competitiveness with rivals such as GlaxoSmithKline and Pfizer.
Although a drugs titan in Japan, Takeda ranks only 14th in the world a position that the groups president is eager to improve. In an exclusive interview with The Times, Yasuchika Hasegawa described a desire to put his group on the global map by using its cash to create a pipeline of blockbuster drugs.

With all these factors mounting, the outlook for OXB is looking very interesting.

Indeed they are - but hopefully the sp will go down to the 28/29p range so that I can buy in, before rebounding on further good news.

More licencing agreements, before long they'll be cash flow positive. A rights is not needed and Oxb is gaining international recognition. A doctor friend of mine recently bought into these, they get all the trade articles which must have impressed her, once again we are at bargain price and any further fall will be sure to trigger takeover talk again.

An anlaysis of the trdes today suggests institutional support at these levels, any further news should propell it back above 40, 45

another large buy 500k at 37

Has anybody read anything lately about OXB ? - something has put the spooks up investors or mms.

It's just shorters IMHO.
UC.

I've just read this item in tonight's Stock Market report from UK-Analyst. Their view is that today's slide in the share price is unwarranted!

Oxford BioMedica, the gene therapy company, saw its shares ease 2.5p to 27.5p as investors bailed out on news of an imminent fundraising. The slide would appear to have been unwarranted, with the company announcing good progress with its registration plans and details of a Phase III trial with its lead cancer immunotherapy, TroVax, in renal cell carcinoma. Meanwhile, it was news of a proposed 20-30 million dollar placing and open offer that concerned investors, who speculated over what level of discount might or might not be applied.

Not sure why the sp reacted so badly to speculation of fundraising. The fundamentals haven't changed and they still have plenty of cash in the bank. They want to fasttrack the trials without delay of signing up a partner (although thats still a possibility) AK is obviously very confident and by going it alone will mean all the more benefit to shareholders, whilst control is very much with OXB. Personally I think going it alone would be the better option and 20-30m worth of shares bought by institutions at a discount is small price to pay, may even be at a premium!! No bad news here, in fact OXB now even more vulnerable to a bid which would be a great shame. Should soon return to 40p and on to 50+ once this glitch has been forgotten.